CRISPR Therapeutics AG (CRSP) Cash Flow Statement

The gap between net income and operating cash flow is widening, with 2026Q2 showing cash burn nearly double the accounting loss. This suggests that non-cash charges like SBC are not the primary driver; rather, working capital swings and possibly timing of collaboration payments are amplifying cash outflows. Investors should monitor whether this reflects a structural shift to commercial operations or a one-time distortion.

The FCF trajectory shows a sharp acceleration in cash consumption, from -$109.4M in 2026Q1 to -$193.5M in 2026Q2, despite a slight improvement in FCF margin due to a revenue uptick. This suggests that operating expenses are scaling faster than any revenue recovery, and the company remains heavily reliant on its cash buffer and external financing. The trend appears consistent with the post-approval commercialization costs and pipeline expansion.

CapEx is negligible, indicating that the company's investments are not in physical assets but in intangible R&D and clinical trials, which are expensed through the income statement. This suggests that the capital intensity of the business is understated by CapEx alone, and the true cash burn is reflected in operating cash flow. The low CapEx also implies that the company is not building significant manufacturing capacity, likely relying on Vertex's infrastructure, which may limit its ability to control costs.

The working capital line is highly volatile, with a massive positive swing in 2024Q1 likely due to a collaboration milestone or receivable collection, followed by persistent negative contributions in recent quarters. This suggests that the company's cash flow is heavily influenced by the timing of payments from partners like Vertex, and not by steady operational efficiency. Investors should expect continued lumpiness in operating cash flow as the company navigates its commercial launch and pipeline milestones.

Capital deployment is entirely focused on funding internal development, with no returns to shareholders. The negligible buyback in 2026Q2 is immaterial, and the absence of dividends is expected for a development-stage biotech. This suggests that management is prioritizing pipeline advancement and commercial scaling over shareholder returns, which is typical but warrants monitoring given the accelerating cash burn.

The cumulative gap between net income and operating cash flow is positive, meaning that accounting losses are larger than actual cash outflows, largely due to stock-based compensation and depreciation. However, this does not imply better cash generation; rather, it reflects the non-cash nature of some expenses. The divergence suggests that the company's cash runway may be longer than net income trends imply, but the accelerating burn in recent quarters is a concern.